2027 ICD-10-CM Diagnosis Code E70.321Tyrosinase positive oculocutaneous albinism

ICD-10-CM Codes›E00–E89›E70-E88›E70

ICD-10-CM E70.321
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

E70.321 is a billable ICD-10-CM diagnosis code for tyrosinase positive oculocutaneous albinism. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 642. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 140 closely related codes. Coders also document this condition as brown oculocutaneous albinism. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.

E70.321 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 23 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 23, ESRD (V21) category 23, ESRD (V24) category 23, and RxHCC Part D (V08) category 43 for payment year 2027.

Code Identity

ICD-10-CM Code
E70.321
Billable Status
Yes — Valid for Submission
Code Describes
Tyrosinase positive oculocutaneous albinism
Short Description
Tyrosinase positive oculocutaneous albinism
Same as the full description in the CMS dataset.
Parent Code
E70.32
Oculocutaneous albinism

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE70Disorders of aromatic amino-acid metabolism
This CodeE70.321Tyrosinase positive oculocutaneous albinism

Medicare Risk Adjustment (HCC)Billing

E70.321 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.

CMS-HCC V28 (Medicare Advantage Payment Model)
Not mapped
Dropped in V28 see all codes that no longer risk-adjust
Prior Model (CMS-HCC V24)
HCC 23
V24 retired last contributed to a Medicare Advantage risk score in payment year 2025
Other CMS Models
PACE (CMS-HCC V22): HCC 23 · ESRD (V21): HCC 23 · ESRD (V24): HCC 23
ESRD V21 weights: 0.013 dialysis, 0.234–0.359 functioning graft · ESRD V24 weights: 0.036 dialysis, 0.217–0.390 functioning graft
Part D (RxHCC)
RxHCC 43 — Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Brown oculocutaneous albinism
  • Rufous albinism
  • Tyrosinase-positive oculocutaneous albinism

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to E70.321: its own notes plus those printed at E70.32, block E70-E88, and Chapter 4. A note printed at a category, block or chapter applies to every code under it.

Applicable To

Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.

  • Albinism II
  • Oculocutaneous albinism ty-pos

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From E70.32 Oculocutaneous albinism applies to 4 codes
From Block E70-E88 Metabolic disorders applies to 286 codes
  • androgen insensitivity syndrome (E34.5-)
  • congenital adrenal hyperplasia (E25.0)
  • hemolytic anemias attributable to enzyme disorders (D55.-)
  • Marfan syndrome (Q87.4-)
  • 5-alpha-reductase deficiency (E29.1)
From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From Block E70-E88 Metabolic disorders applies to 286 codes
  • Ehlers-Danlos syndromes (Q79.6-)

Notes

General instructions on how these codes are used.

From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name E70.321, its category, or a range that includes it.

Excludes1 4

These codes carry an Excludes1 note naming E70.321: they are not reported together with it, unless the two conditions are unrelated.

  • E72 Other disorders of amino-acid metabolism
    aromatic amino-acid metabolism (E70.-) names E70.-, which includes this code
  • R79 Other abnormal findings of blood chemistry
    specific findings indicating disorder of amino-acid metabolism (E70-E72) names E70-E72, which includes this code
  • R79.83 Abnormal findings of blood amino-acid level
    disorders of amino-acid metabolism (E70-E72) names E70-E72, which includes this code
  • Block R80-R82 Abnormal findings on examination of urine, without diagnosis
    specific findings indicating disorder of amino-acid metabolism (E70-E72) names E70-E72, which includes this code

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END016
Other specified and unspecified nutritional and metabolic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Albinism, Oculocutaneous

    heterogeneous group of autosomal recessive disorders comprising at least four recognized types, all having in common varying degrees of hypopigmentation of the skin, hair, and eyes. the two most common are the tyrosinase-positive and tyrosinase-negative types.

Patient EducationClinical

Eye Diseases

Even if your eyes feel healthy, you could have a problem and not know it. That's why regular eye exams are so important. Refractive errors are the most common type of vision problem that makes it hard to see clearly. But some eye conditions or diseases don't have any symptoms and can lead to a permanent loss of vision.

The full article covers:

  • What diseases can affect the eye?
  • What are the symptoms of eye diseases?
  • Who is more likely to develop eye diseases?
  • What are the treatments for eye diseases?
  • Can eye diseases be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E70.321 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
270.2 Arom amin-acid metab NEC
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About E70.321Overview

What is the ICD-10 code for tyrosinase positive oculocutaneous albinism?

The ICD-10-CM code for tyrosinase positive oculocutaneous albinism is E70.321 (sometimes written as E70321). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is E70.321 (Oculocutaneous albinism) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report tyrosinase positive oculocutaneous albinism on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does E70.321 group to?

When tyrosinase positive oculocutaneous albinism is the principal diagnosis on an inpatient stay, it groups to MS-DRG 642 (inborn and Other Disorders of Metabolism), which carries a relative weight of 1.3226. Higher weights mean higher Medicare reimbursement.

Is E70.321 a CC or MCC?

CMS lists E70.321 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 140 closely related codes in its exclusion list.

Can E70.321 be reported with E70.330?

Not as a rule. The Excludes1 note at E70.32, which applies to E70.321, lists "Chediak-Higashi syndrome (E70.330)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

Does E70.321 risk-adjust for Medicare Advantage payment?

Not for Medicare Advantage. E70.321 mapped to HCC 23 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V21) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V24) category 23 (Other Significant Endocrine and Metabolic Disorders), and RxHCC Part D (V08) category 43 (Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders).